Hologic Inc. (NASDAQ: HOLX) is experiencing a challenging period as its stock recently hit a 52-week low, trading at $57.28 as of May 2, 2025. The decline is attributed to several factors, including the impact of tariffs and geopolitical tensions. These pressures have resulted in the company's need to reassess its financial outlook.
The company's stock was downgraded by major analysts, with Citigroup lowering its rating from "Buy" to "Neutral" in October 2024, expressing concerns about overestimated growth projections for fiscal year 2025, according to investing.com. Similarly, Needham downgraded the stock from "Buy" to "Hold" in March 2025, citing slower growth in the Breast Health segment and anticipated impacts from policy changes.
In response to these challenges, Hologic revised its fiscal year 2025 revenue guidance in February, reducing expectations by $100 million. This decision was influenced by a stronger U.S. dollar and anticipated lower sales in the Breast Health sector. Additionally, potential tariffs on goods from Mexico and geopolitical challenges, such as disruptions with partners including PEPFAR, are expected to affect the company's financials. These external pressures, along with revised guidance, reflect the company's adaption to the current economic landscape, as reported by in.marketscreener.com.